Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Diarrhoea is one of the most serious complications in hereditary ATTR (ATTRv) amyloidosis. However, its precise pathomechanism remains unknown. The present study investigated the involvement of bile acid in diarrhoea along with the therapeutic effect of colestimide, a bile acid sequestrant, in ATTRv amyloidosis.Methods We prospectively enrolled 19 ATTRv amyloidosis patients (9 with refractory diarrhoea and 10 without diarrhoea) and 20 healthy individuals for measurements of serum 7a-hydroxy-4-cholesten-3-one (C4) levels. The patients with diarrhoea were then treated with oral colestimide (1.5 g twice daily) for 28 days. The frequency of diarrhoea and C4 level were evaluated before and after colestimide treatment.Results Mean serum C4 level was significantly higher in ATTRv patients with diarrhoea (62.3 ng/mL) than in ATTRv patients without diarrhoea (24.0 ng/mL, p = 0.03). Colestimide treatment significantly decreased mean diarrhoea frequency (pre-treatment period: 9.1 times/week, colestimide treatment period, 6.6 times/week, p = 0.04) and increased mean C4 level (before treatment: 66.2 ng/mL, after treatment: 187.1 ng/mL, p = 0.02).Conclusions Bile acid status was significantly associated with diarrhoea in ATTRv amyloidosis. Colestimide and other bile acid sequestrants may reduce diarrhoea frequency in afflicted patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis
- Date Crossref
- 20/11/2024
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shinshu University Department of Medicine (Neurology and Rheumatology) pays non établi dans la noticeUniversité ou école supérieure
-
Niigata University of Pharmacy and Medical and Life Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Applied Life Sciences Laboratory of Functional and Analytical Food Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medical Technology Division of Bio-Analytical Chemistry pays non établi dans la noticeUniversité ou école supérieure
Department of Medicine (Neurology and Rheumatology) — Shinshu University, Niigata University of Pharmacy and Medical and Life Sciences et Laboratory of Functional and Analytical Food Sciences — Faculty of Applied Life Sciences, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.